Expert RA upgraded PROMOMED DM's credit rating to ruA
30.07.2025
30.07.2025
July 30, 2025, Moscow — PJSC PROMOMED (MOEX: PRMD) (hereinafter referred to as "PROMOMED", the "Company", and together with its subsidiaries— the "Group") became one of the leaders in the CURSOR rating, reflecting the dynamics of drug portfolios of the largest Russian pharmaceutical manufacturers.
The rating[1] is based on the current registration certificates (RU) issued according to the rules of the EAEU, based on information from the State Register of Medicines (GRLS) and the Cursor database.
PROMOMED demonstrates one of the best indicators in terms of the number of new registration certificates issued in 2024-2025, and occupies a leading position in the categories of the drug portfolio.
The company has been named the leader in the number of international nonproprietary names (INN) in parenteral administration forms, a critically important area for the hospital segment and emergency therapy. This area traditionally requires high technological maturity of production and strict adherence to quality standards.
Executive DirectorPROMOMEDEduard Kasyan:
"The CURSOR rating reflects the key changes taking place in the market and confirms the correctness of the Company's chosen development strategy, namely, the development and launch of innovative socially significant drugs in the most sought-after therapeutic segments."
[1] https://cursor-is.ru/ru/reports/TOP-50_otechestvenn_proizvoditelei_LS_2025.pdf
Stay informed
Stay informed
Get the most interesting news and publications first!
Sent successfully!
Press office
To request a press release or interview, please contact our press office